| abstract |
1. Dimeric compound for the formation of a multimer capable of reproducing the effector function of aggregated IgG during multimerization through a multimerizing region, which contains identical monomers, where each monomer contains from the N-terminal to the C-terminal: (a) at least one monomer of the multimerizing region, which upon dimerization forms a multimerizing region, and wherein the multimerizing region is an IgG2 hinge region or an isoleucine zipper; and (b) at least one Fc domain comprising a CH2 domain and a CH3 domain of IgG1, IgG3 or IgG4, which, upon dimerization, is capable of binding to the Fc receptor. 2. A dimeric compound according to claim 1, wherein the compound does not contain an antigen binding Fab domain. The dimeric compound of claim 1, wherein the Fc domain further comprises a hinge region domain of IgG1, IgG3 or IgG4.4. The dimeric compound of claim 1, wherein the monomer of the multimerizing region is an IgG2.5 hinge region. The dimeric compound of claim 1, wherein the multimerizing region is isoleucine zipper. A dimeric compound according to claim 1, containing two or more Fc domains. The dimeric compound of claim 1, wherein the compound is capable of binding one or more human Fcγ receptor I, human Fcγ receptor II, human Fcγ receptor III, human Fcγ receptor IV, FcRN, or non-human equivalents. The dimeric compound of claim 7, wherein the human Fcγ receptor III is FcγRIIIa. 9. The dimeric compound of claim 1, wherein the Fc domain comprises a hinge region of IgG1, CH2 IgG1 and CH3 IgG1.10. The dimeric compound of claim 1, wherein the identical monomers contain the protein of SEQ ID NO: 61.11. The dimeric compound of claim 1, wherein the identical monomers contain the protein of SEQ ID NO: 67.12. M |